论文部分内容阅读
肝移植术后乙型肝炎(乙肝)再感染是影响肝移植预后的主要因素之一。乙肝免疫球蛋白(HB IG)及拉米夫定的应用已使乙肝相关性肝病成为肝移植的适应证。但是,HB IG及拉米夫定用于预防肝移植后乙肝复发存在不少缺点。同时非乙肝相关性肝病的受者也可以通过输血、供肝及其他途径感染乙肝。因此,寻找更经济、有效、安全可靠、更具潜力的预防策略,减少或停用HB IG及拉米夫定,成为学者们的研究目标,而乙肝疫苗即是研究热点之一。因此,笔者对就近年来乙肝疫苗用于预防肝移植术后乙肝再感染的研究作一简要综述。
Hepatitis B (HBV) re-infection after liver transplantation is one of the main factors affecting the prognosis of liver transplantation. The use of HBIG and lamivudine has made HBV-related liver disease a hallmark of liver transplantation. However, HB IG and lamivudine for the prevention of hepatitis B recurrence after liver transplantation there are many shortcomings. At the same time, recipients of non-hepatitis B-related liver disease can also infect hepatitis B through blood transfusion, donor liver and other means. Therefore, looking for more economical, effective, safe and reliable, more potential prevention strategies to reduce or stop HB IG and lamivudine has become the research goal of scholars, and hepatitis B vaccine is one of the hot spots. Therefore, the author of hepatitis B vaccine in recent years for the prevention of hepatitis B re-infection after liver transplantation for a brief review of the study.